Cancer Research U.K. (CRUK) will collaborate with Aleta Biotherapeutics for the early phase clinical development of the ALETA-001, which is Aleta Biotherapeutics’ Cancer therapy candidate.ALETA-001 is a CAR-T cell developed by Aleta Biotherapeutics to treat patients suffering from B-cell Cancer.
According to the agreement, the CRUK will provides financial support, sponsor, and conduct the second phase clinical trials of ALETA-001. The two phases of the clinical trials will be done by the Cellular and CAR-T therapy team. Dr. Amit Patel will lead the team. The first and second phase clinical trials will be conducted at Christie NHS Foundation Trust.
Paul Rennert, the co-founder, and chief scientific officer of Aleta said, said there is an urgent need for new therapies that will help patients with B-cell Cancer like leukemia and lymphoma.The latest trail discovery will be the first of its kind that will reboot CAR-T cell therapy, he added.